Recruiting
PHASE3
INTERVENTIONAL
NCT07036172
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.
Interventions
Name:
HDM1702
Type:
DRUG
Description:
Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
Name:
Wegovy ®
Type:
DRUG
Description:
Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
Primary Outcomes
Measure:
The percentage change in body weight from baseline to week 44
TimeFrame:
week 44
Description:
Trial Information
NCT ID
NCT07036172
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Last Updated
December 15, 2025